Department of Neurodegenerative Science, Van Andel Institute, Grand Rapids, Michigan, USA.
Division of Psychiatry and Behavioral Medicine, Michigan State University College of Human Medicine, Grand Rapids, MI, USA.
Brain. 2021 May 7;144(4):1067-1081. doi: 10.1093/brain/awab028.
The majority of genome-wide association studies have been conducted using samples with a broadly European genetic background. As a field, we acknowledge this limitation and the need to increase the diversity of populations studied. A major challenge when designing and conducting such studies is to assimilate large samples sizes so that we attain enough statistical power to detect variants associated with disease, particularly when trying to identify variants with low and rare minor allele frequencies. In this review, we aimed to illustrate the benefits to genetic characterization of Alzheimer's disease, in researching currently understudied populations. This is important for both fair representation of world populations and the translatability of findings. To that end, we conducted a literature search to understand the contributions of studies, on different populations, to Alzheimer's disease genetics. Using both PubMed and Alzforum Mutation Database, we systematically quantified the number of studies reporting variants in known disease-causing genes, in a worldwide manner, and discuss the contributions of research in understudied populations to the identification of novel genetic factors in this disease. Additionally, we compared the effects of genome-wide significant single nucleotide polymorphisms across populations by focusing on loci that show different association profiles between populations (a key example being APOE). Reports of variants in APP, PSEN1 and PSEN2 can initially determine whether patients from a country have been studied for Alzheimer's disease genetics. Most genome-wide significant associations in non-Hispanic white genome-wide association studies do not reach genome-wide significance in such studies of other populations, with some suggesting an opposite effect direction; this is likely due to much smaller sample sizes attained. There are, however, genome-wide significant associations first identified in understudied populations which have yet to be replicated. Familial studies in understudied populations have identified rare, high effect variants, which have been replicated in other populations. This work functions to both highlight how understudied populations have furthered our understanding of Alzheimer's disease genetics, and to help us gauge our progress in understanding the genetic architecture of this disease in all populations.
大多数全基因组关联研究都是使用具有广泛欧洲遗传背景的样本进行的。作为一个领域,我们认识到这一局限性以及增加研究人群多样性的必要性。在设计和进行此类研究时,主要的挑战是整合大量样本,以便我们获得足够的统计能力来检测与疾病相关的变异,特别是当试图识别低频和罕见的次要等位基因频率的变异时。在这篇综述中,我们旨在说明对目前研究较少的人群进行阿尔茨海默病遗传特征研究的好处。这对于公平代表世界人口和发现的可转化性都很重要。为此,我们进行了文献检索,以了解不同人群的研究对阿尔茨海默病遗传学的贡献。我们使用 PubMed 和 Alzforum Mutation Database 系统地量化了以全球范围报告已知疾病相关基因中变异的研究数量,并讨论了在研究较少的人群中进行研究对该疾病中新型遗传因素的识别的贡献。此外,我们通过关注在人群之间表现出不同关联特征的基因座(一个关键示例是 APOE),比较了不同人群中全基因组显著单核苷酸多态性的影响。APP、PSEN1 和 PSEN2 中的变异报告最初可以确定一个国家的患者是否已经接受过阿尔茨海默病遗传学研究。在其他人群的此类研究中,大多数非西班牙裔白人全基因组关联研究中的全基因组显著关联都未达到全基因组显著水平,其中一些研究表明了相反的作用方向;这很可能是由于获得的样本量要小得多。然而,也有一些首先在研究较少的人群中发现的全基因组显著关联尚未得到复制。在研究较少的人群中进行的家族研究已经确定了罕见的、高影响的变异,这些变异在其他人群中得到了复制。这项工作不仅突出了研究较少的人群如何进一步了解阿尔茨海默病遗传学,还帮助我们评估了我们在理解所有人群中这种疾病的遗传结构方面的进展。